Kiora Stock Story

KPRX
 Stock
  

USD 0.15  0.01  6.25%   

3M would recover faster from the new pull down as its shares price went up 0.71% to Kiora Pharmaceuticals's 4.26%As many rational traders are trying to avoid healthcare space, it makes sense to break down Kiora Pharmaceuticals a little further and understand how it stands against 3M and other similar entities. We are going to inspect some of the competitive aspects of both Kiora and 3M.
Published over a month ago
View all stories for Kiora Pharmaceuticals | View All Stories

Will 3M (NYSE:MMM) and Kiora Pharmaceuticals (NASDAQ:KPRX) deliver in August?

By analyzing existing basic indicators between Kiora Pharmaceuticals and 3M, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in 3M with a short position in Kiora Pharmaceuticals. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.
One of the ways to look at asset utilization of Kiora is to check how much profit was generated for every dollar of assets it reports. Kiora Pharmaceuticals secures a negative usage of assets of -39.64 %, losing $0.4 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Kiora Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.

Watch out for price decline

Please consider monitoring Kiora Pharmaceuticals on a daily basis if you are holding a position in it. Kiora Pharmaceuticals is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Kiora Pharmaceuticals stock to be traded above the $1 level to remain listed. If Kiora Pharmaceuticals stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Kiora Pharmaceuticals's Liquidity

Kiora Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Kiora Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Kiora Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Kiora Pharmaceuticals's total debt and its cash.

How does Kiora utilize its cash?

To perform a cash flow analysis of Kiora Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Kiora Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Kiora Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Kiora Pharmaceuticals Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Kiora Pharmaceuticals reported Net Cash Flow from Operations of (10.68 Million) in 2021

Payment of 108 shares by Romano Sarah of Kiora Pharmaceuticals subject to Rule 16b-3

Legal trades by Kiora Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Kiora insider trading alert for payment of common stock by Romano Sarah, Chief Financial Officer, on 11th of February 2022. This event was filed by Kiora Pharmaceuticals Inc with SEC on 2022-02-11. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Now, let's check Kiora Pharmaceuticals revenue. Based on the latest financial disclosure, Kiora Pharmaceuticals reported 12.06 K of revenue. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The revenue for all United States stocks is 100.0% higher than that of Kiora Pharmaceuticals. As for 3M we see revenue of 35.33 B, which is much higher than that of the Biotechnology

MMM
35.3 B
KPRX12,0603.3E-5
Sector742.91 Million2.06
MMM35.33 Billion97.94

Time to sell Kiora Pharmaceuticals is now

The mean deviation is down to 4.51 as of today. Kiora Pharmaceuticals is displaying above-average volatility over the selected time horizon. Investors should scrutinize Kiora Pharmaceuticals independently to ensure intended market timing strategies are aligned with expectations about Kiora Pharmaceuticals volatility. Kiora Pharmaceuticals is a potential penny stock. Although Kiora Pharmaceuticals may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Kiora Pharmaceuticals. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Kiora instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Our Bottom Line On Kiora Pharmaceuticals

While some firms in the biotechnology industry are either recovering or due for a correction, Kiora may not be as strong as the others in terms of longer-term growth potentials. With a somewhat neutral outlook on your 90 days horizon, it may be better to hold off any trading activity and neither buy new shares of Kiora nor quit your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Kiora Pharmaceuticals.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Kiora Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com